The interaction between atherosclerosis and commensal microbes through leaky gut syndrome (LGS), which is characterized by impaired intestinal permeability and the introduction of undesired pathogens into the body, has not been fully elucidated. Our aim was to investigate the potential role of a ClC-2 chloride channel activator, lubiprostone, which is reported to have beneficial effects on LGS, in the development of atherosclerosis in apolipoprotein E-deficient (ApoE-/-) mice. After a 15-week feeding period of a Western diet (WD), ApoE-/- mice were treated with a Western-type diet (WD) alone or WD with oral supplementation of lubiprostone for 10 weeks. This feeding protocol was followed by experimental evaluation of LGS and atherosclerotic lesions in the aorta. In mice with lubiprostone, in vivo translocation of orally administered 4-kDa FITC-dextran was significantly improved, and RNA expression of the epithelial tight junction proteins, Zo-1 and occludin, was significantly up-regulated in the ileum, compared to the WD alone group, suggesting a possible reversal of WD-induced intestinal barrier dysfunction. As a result, WD-induced exacerbation of atherosclerotic lesion formation was reduced by 69% in longitudinally opened aortas and 26% in aortic root regions. In addition, there was a significant decrease in circulating immunoglobulin level, followed by an attenuation of inflammatory responses in the perivascular adipose tissue, as evidenced by reduced expression of pro-inflammatory cytokines and chemokines. Lubiprostone attenuates atherosclerosis by ameliorating LGS-induced inflammation through the restoration of the intestinal barrier. These findings raise the possibility of targeting LGS for the treatment of atherosclerosis.

+More

westerntype diet leaky gut syndrome proinflammatory cytokines wdinduced intestinal barrier immunoglobulin 4kda clc2 chloride channel activator lubiprostone epithelial tight junction proteins zo1 commensal microbes root lgs undesired pathogens lesion rna

Kentaro Arakawa,Tomoaki Ishigami,Michiko Nakai-Sugiyama,Lin Chen,Hiroshi Doi,Tabito Kino,Shintaro Minegishi,Sae Saigoh-Teranaka,Rie Sasaki-Nakashima,Kiyoshi Hibi,Kazuo Kimura,Kouichi Tamura,.Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice.. 14 (6),.

Kentaro Arakawa,Tomoaki Ishigami,Michiko Nakai-Sugiyama,Lin Chen,Hiroshi Doi,Tabito Kino,Shintaro Minegishi,Sae Saigoh-Teranaka,Rie Sasaki-Nakashima,Kiyoshi Hibi,Kazuo Kimura,Kouichi Tamura,"Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice." 14

Kentaro Arakawa,Tomoaki Ishigami,Michiko Nakai-Sugiyama,Lin Chen,Hiroshi Doi,Tabito Kino,Shintaro Minegishi,Sae Saigoh-Teranaka,Rie Sasaki-Nakashima,Kiyoshi Hibi,Kazuo Kimura,Kouichi Tamura,"Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice."